Literature DB >> 12702666

Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons.

Pepijn van den Munckhof1, Kelvin C Luk, Line Ste-Marie, Jane Montgomery, Pierre J Blanchet, Abbas F Sadikot, Jacques Drouin.   

Abstract

Mesencephalic dopaminergic (MesDA) neurons play crucial roles in motor and behavioral processes; their loss in Parkinson's disease (PD) results in striatal dopamine (DA) deficiency and hypokinetic movement disorder. The Pitx3 homeobox gene is expressed in the MesDA system. We now show that only a subset of MesDA neurons express Pitx3 and that in Pitx3-deficient aphakia mice, this subset is progressively lost by apoptosis during fetal (substantia nigra, SN) and postnatal (ventral tegmental area) development, resulting in very low striatal DA and akinesia. Similar to human PD, dorsal SN neurons (which are Pitx3 negative) are spared in mutant mice. Thus, Pitx3 defines a pathway for survival of neurons that are implicated in PD and that are required for spontaneous locomotor activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702666     DOI: 10.1242/dev.00464

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  98 in total

1.  Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a.

Authors:  Gonçalo Castelo-Branco; Joseph Wagner; Francisco J Rodriguez; Julianna Kele; Kyle Sousa; Nina Rawal; Hilda Amalia Pasolli; Elaine Fuchs; Jan Kitajewski; Ernest Arenas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

2.  SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells.

Authors:  Julianna Kele; Emma R Andersson; J Carlos Villaescusa; Lukas Cajanek; Clare L Parish; Sonia Bonilla; Enrique M Toledo; Vitezslav Bryja; Jeffrey S Rubin; Akihiko Shimono; Ernest Arenas
Journal:  Stem Cells       Date:  2012-05       Impact factor: 6.277

Review 3.  Modulation of dopaminergic neuronal differentiation from sympathoadrenal progenitors.

Authors:  Vladimir Vukicevic; Maria F Rubin de Celis; Gabriela Diaz-Valencia; Stefan R Bornstein; Monika Ehrhart-Bornstein
Journal:  J Mol Neurosci       Date:  2012-03-25       Impact factor: 3.444

4.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

5.  L-dopa reverses behavioral deficits in the Pitx3 mouse fetus.

Authors:  Gale A Kleven; Heather M Booth; Marco Voogd; April E Ronca
Journal:  Behav Neurosci       Date:  2014-08-25       Impact factor: 1.912

6.  Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.

Authors:  Yunmin Ding; Lisa Won; Jonathan P Britt; Sean Austin O Lim; Daniel S McGehee; Un Jung Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

7.  Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.

Authors:  Jisook Moon; Hyun-Seob Lee; Jun Mo Kang; Junpil Park; Amanda Leung; Sunghoi Hong; Sangmi Chung; Kwang-Soo Kim
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

8.  A MicroRNA feedback circuit in midbrain dopamine neurons.

Authors:  Jongpil Kim; Keiichi Inoue; Jennifer Ishii; William B Vanti; Sergey V Voronov; Elizabeth Murchison; Gregory Hannon; Asa Abeliovich
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

Review 9.  Induced neuronal reprogramming.

Authors:  Cheen Euong Ang; Marius Wernig
Journal:  J Comp Neurol       Date:  2014-05-21       Impact factor: 3.215

Review 10.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.